These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19220742)

  • 1. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
    Corey KE; Shah N; Misdraji J; Abu Dayyeh BK; Zheng H; Bhan AK; Chung RT
    Liver Int; 2009 May; 29(5):748-53. PubMed ID: 19220742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation.
    Rimola A; Londoño MC; Guevara G; Bruguera M; Navasa M; Forns X; García-Retortillo M; García-Valdecasas JC; Rodes J
    Transplantation; 2004 Sep; 78(5):686-91. PubMed ID: 15371669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic effect of angiotensin blockers in hypertensive hepatitis C patients.
    Bahde R; Kapoor S
    Liver Int; 2009 Nov; 29(10):1597; author reply 1598. PubMed ID: 19744164
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
    Transplant Proc; 2013; 45(6):2331-6. PubMed ID: 23953545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
    Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai R; McCullough AJ; Dasarathy S
    Liver Int; 2015 Mar; 35(3):979-85. PubMed ID: 24905085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.
    Abu Dayyeh BK; Yang M; Dienstag JL; Chung RT
    Dig Dis Sci; 2011 Feb; 56(2):564-8. PubMed ID: 21136163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
    Parreira NA; Ramalho FS; Augusto MJ; Silva DM; Prado CM; Elias Júnior J; Rodrigues V; Ramalho LNZ
    Exp Parasitol; 2018 Aug; 191():9-18. PubMed ID: 29890165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation.
    Cholongitas E; Vibhakorn S; Lodato F; Burroughs AK
    Liver Int; 2010 Feb; 30(2):334-5. PubMed ID: 19515217
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
    Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
    J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis.
    Imakiire T; Kikuchi Y; Yamada M; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Oda T; Suzuki S; Miura S
    Hypertens Res; 2007 Jul; 30(7):635-42. PubMed ID: 17785932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential hypertension and chronic viral hepatitis.
    Parrilli G; Manguso F; Orsini L; Coccoli P; Vecchione R; Terracciano L; De Luca N; Cirillo N; Abazia C; Budillon G; Marchesini G
    Dig Liver Dis; 2007 May; 39(5):466-72. PubMed ID: 17369113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
    Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
    BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    Pelusi S; Petta S; Rosso C; Borroni V; Fracanzani AL; Dongiovanni P; Craxi A; Bugianesi E; Fargion S; Valenti L
    PLoS One; 2016; 11(9):e0163069. PubMed ID: 27649410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of hepatic fibrosis through captopril and enalapril in the livers of bile duct ligated rats.
    Karimian G; Mohammadi-Karakani A; Sotoudeh M; Ghazi-Khansari M; Ghobadi G; Shakiba B
    Biomed Pharmacother; 2008 Jun; 62(5):312-6. PubMed ID: 18191530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.